Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2

Eur Urol. 1993;24(4):466-70. doi: 10.1159/000474351.


A total of 294 patients with metastatic prostatic cancer were randomized prospectively in a Scandinavian multicenter study to either bilateral orchiectomy+placebo or orchiectomy+cyproterone acetate (CPA). The study was double blind. Patients with histologically verified prostatic cancer, with diagnosed skeletal metastases on X-ray or bone scintigrams and histological grade 1 and 2 were included: T0-4NXM1G1-2. 273 evaluable patients were followed either to progression, death or for a period of 3 years. 195 of these patients showed disease progression during the 3-year treatment period, 29 had stable disease and 49 patients experienced disease remission. The Kaplan-Meier analyses showed that time to progression as well as time to death for patients treated with castration+placebo are identical to that for patients treated with castration+PCA. Total androgen blockade with this antiandrogen was not superior to the standard orchiectomy treatment.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Bone Neoplasms / secondary
  • Cyproterone Acetate / therapeutic use*
  • Double-Blind Method
  • Humans
  • Male
  • Orchiectomy*
  • Prospective Studies
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Survival Rate


  • Cyproterone Acetate